Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

June M. McKoy, MD, JD, MPH, MBA, Dustin B Liebling, BA, Alfred W. Rademaker, PhD, Bing Bing Weitner, MS, Beatrice J. Edwards, MD, MPH, Steven M. Belknap, MD, Andrew Thurston, MD, Monica Boen, MD, Katrina-Marie E Tulas, BA, Judith M McKoy-Bent, BA, BSN, Jowella Pineda, MD, Dennis P. West, PhD

Blood (2012) 120 (21): 4692.

https://doi.org/10.1182/blood.V120.21.4692.4692

Published: 2012

Journal Articles

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

Charles L Bennett, MD, PhD, Athena T Samaras, BA, June M McKoy, MD, JD, MPH, Beatrice J Edwards, MD, FACP, Mi Zheng, Matthew J Fisher, BA, Simone N Boyle, BA, Steven M Trifilio, RPh, Monica Boen, BA, Dianne Deleon, BA, Dennis P West, PhD

Blood (2009) 114 (22): 4538.

https://doi.org/10.1182/blood.V114.22.4538.4538

Published: 2009

Journal Articles

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Charles L. Bennett, MD, PhD, Ari Polish, MD, Athena T Samaras, BA, Mi Zheng, Dennis P West, PhD, Steven M Trifilio, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Matthew J Fisher, June M McKoy, MD, JD, MPH

Blood (2009) 114 (22): 4555.

https://doi.org/10.1182/blood.V114.22.4555.4555

Published: 2009

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3339.

https://doi.org/10.1182/blood.V110.11.3339.3339

Published: 2007

NARROW

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Email alerts

ASH Publications

American Society of Hematology

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only